My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 246

    1.

    Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

    Johnson JA, Majumdar SR, Simpson SH, Toth EL.

    Diabetes Care. 2002 Dec;25(12):2244-8.PMID: 12453968 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

    Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

    Diabetes Care. 2006 Feb;29(2):254-8.PMID: 16443869 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

    Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA.

    Diabetes Care. 2005 Oct;28(10):2345-51.PMID: 16186261 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.

    Eurich DT, Simpson SH, Majumdar SR, Johnson JA.

    Pharmacotherapy. 2005 Jun;25(6):810-6.PMID: 15927899 [PubMed - indexed for MEDLINE]Related articles

    5.

    Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.

    Johnson JA, Simpson SH, Toth EL, Majumdar SR.

    Diabet Med. 2005 Apr;22(4):497-502.PMID: 15787679 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus.

    Gosmanova EO, Canada RB, Mangold TA, Rawls WN, Wall BM.

    Am J Med Sci. 2008 Sep;336(3):241-7.PMID: 18794619 [PubMed - indexed for MEDLINE]Related articles

    7.

    Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.

    Kahler KH, Rajan M, Rhoads GG, Safford MM, Demissie K, Lu SE, Pogach LM.

    Diabetes Care. 2007 Jul;30(7):1689-93. Epub 2007 Apr 17.PMID: 17440170 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.

    Fisman EZ, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M.

    Cardiology. 1999;91(3):195-202.PMID: 10516414 [PubMed - indexed for MEDLINE]Related articles

    9.

    Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.

    Riedel AA, Heien H, Wogen J, Plauschinat CA.

    Pharmacotherapy. 2007 Aug;27(8):1102-10.PMID: 17655510 [PubMed - indexed for MEDLINE]Related articles

    10.

    Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis.

    Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA.

    Drugs Aging. 2008;25(7):611-22.PMID: 18582148 [PubMed - indexed for MEDLINE]Related articles

    11.

    Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.

    Koro CE, Bowlin SJ, Weiss SR.

    Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):697-703.PMID: 15654719 [PubMed - indexed for MEDLINE]Related articles

    12.

    Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.

    Yurgin N, Secnik K, Lage MJ.

    Clin Ther. 2007 Feb;29(2):316-25.PMID: 17472823 [PubMed - indexed for MEDLINE]Related articles

    13.

    Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.

    Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA.

    CMAJ. 2006 Jan 17;174(2):169-74.PMID: 16415461 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up.

    Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A, Kohanovski M, Rotzak R, Schneider H, Behar S, Motro M.

    Clin Cardiol. 2001 Feb;24(2):151-8.PMID: 11460818 [PubMed - indexed for MEDLINE]Related articles

    15.

    Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen.

    Rendell MS, Glazer NB, Ye Z.

    J Diabetes Complications. 2003 Jul-Aug;17(4):211-7.PMID: 12810245 [PubMed - indexed for MEDLINE]Related articles

    16.

    Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.

    Gulliford M, Latinovic R.

    Diabetes Metab Res Rev. 2004 May-Jun;20(3):239-45.PMID: 15133756 [PubMed - indexed for MEDLINE]Related articles

    17.

    Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

    Lewin A, Lipetz R, Wu J, Schwartz S.

    Clin Ther. 2007 May;29(5):844-55.PMID: 17697903 [PubMed - indexed for MEDLINE]Related articles

    18.

    Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.

    Evans JM, Ogston SA, Emslie-Smith A, Morris AD.

    Diabetologia. 2006 May;49(5):930-6. Epub 2006 Mar 9.PMID: 16525843 [PubMed - indexed for MEDLINE]Related articles

    19.

    Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies.

    Rao AD, Kuhadiya N, Reynolds K, Fonseca VA.

    Diabetes Care. 2008 Aug;31(8):1672-8. Epub 2008 May 5.PMID: 18458139 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.

    McAlister FA, Eurich DT, Majumdar SR, Johnson JA.

    Eur J Heart Fail. 2008 Jul;10(7):703-8. Epub 2008 Jun 19.PMID: 18571471 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity